Health & Pharmaceuticals
Switzerland has approved Coartem Baby, the first-ever malaria treatment specifically designed for newborns and infants, marking a milestone in pediatric care. This formulation targets infants weighing 2–5 kg, typically from birth to under 6 months, a demographic previously excluded from clinical trials and vaccine coverage.
Developed by pharmaceutical giant Novartis, in collaboration with Medicines for Malaria Venture (MMV) and other global health partners, Coartem Baby is a pediatric version of the artemether-lumefantrine combination.
Its primary goal is to bridge the treatment gap for the most vulnerable age group affected by malaria. Following Switzerland’s approval, eight African countries are expected to fast-track its regulatory clearance, given the high burden of infant malaria on the continent.
Course Purchase Query 